Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.17 - $12.57
Previous CloseN/A
Volume477.34K
Average Volume (3M)1.17M
Market Cap
$269.41M
Enterprise Value$256.10M
Total Cash (Recent Filing)$24.97M
Total Debt (Recent Filing)$21.09M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 08, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding92,673,134
10 Day Avg. Volume1,143,907
30 Day Avg. Volume1,173,564
Standard Deviation0.21
R-Squared0.27
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.05K
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$17.75Price Target Upside351.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCOMPASS Pathways raised $140M in net proceeds for the sale of shares and warrants, which extends its financial runway through the 26-week data readout for its confirmatory COMP360 pivotal program.
Product DevelopmentCOMPASS Pathways is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered.
Bears Say
Stock ValuationThe stock price target has been adjusted from $23 to $15 primarily due to dilution from a recent offering.
---
Ownership Overview
22.03% Insiders
0.22% Mutual Funds
23.02% Other Institutional Investors
52.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $3.17 and its highest was $12.57 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $269.41M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 08, 2025 which is in 66 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Feb 27, 2025. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.626 by -$0.004.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.49.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 92,673,134 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.626. Following the earnings report the stock price went up 5.946%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
---
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (351.65% Upside)
$17.75 (351.65% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 373.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.22%
12-Months-Change
Fundamentals
Return on Equity
-81.56%
Trailing 12-Months
Asset Growth
-22.58%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
CMPS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights COMPASS Pathways' solid financial position and progress in clinical trials, particularly for TRD and PTSD, with strategic collaborations enhancing market insights. However, increased net loss and operational costs present financial challenges.Read More>---
CMPS Stock 12 Month Forecast
Average Price Target
$17.75
▲(351.65% Upside)
Technical Analysis
Best Analysts Covering CMPS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-32.19%
reiterated a buy rating last month
Copying Elemer Piros's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -32.19% per trade.
---